Degrading a Key Inflammatory Protein: MRT-8102 Phase 1 Trial Reduces Multiple Biomarkers

Can lowering inflammatory signals in the blood also reduce damage to blood vessels? On October 1, Monte Rosa Therapeutics announced Phase 1 trial results for its oral drug candidate MRT-8102: four weeks of treatment reduced multiple inflammatory biomarkers in participants with obesity and elevated cardiovascular risk. The results support the drug’s ability to affect its intended pathway in humans, but do not yet demonstrate that it can reduce heart attacks, strokes, or other clinical events.

MRT-8102 uses a “molecular glue” degradation strategy to prompt cells to clear the NEK7 protein. NEK7 is involved in assembling the NLRP3 inflammasome; once activated, this intracellular mechanism promotes the release of inflammatory signals such as IL-1β. The company’s development approach is to intervene at this step and reduce multiple downstream signals simultaneously, rather than block only a single inflammatory molecule.

GFORCE-1 enrolled 108 participants, randomly assigned to daily doses of 5, 20, or 40 milligrams or placebo, with 27 participants per group. Four weeks of treatment were followed by four weeks of safety follow-up. Participants had obesity and elevated C-reactive protein (CRP), but were not required to have diagnosed atherosclerotic cardiovascular disease. This was therefore a study exploring drug responses in a high-risk population and cannot be directly regarded as an efficacy trial in patients with coronary artery disease. The primary endpoints were safety and tolerability, with changes in CRP and pharmacokinetics as secondary endpoints; the other multiple biomarkers were assessed in exploratory analyses.

The company reported that, at week four, median NEK7 degradation in peripheral blood T cells was approximately 80% to 90% across the three dose groups. Median reductions in high-sensitivity CRP and IL-6 were 85% and 54%, respectively; calprotectin, S100A12, and serum amyloid A also declined. Some markers approached baseline values in a separate group of healthy volunteers, but this comparison across populations does not demonstrate that vascular plaques had shrunk or become more stable.

The safety data need to be interpreted alongside treatment discontinuations. No serious adverse events were reported during the eight-week observation period. Treatment-emergent adverse events occurred in 33% of drug-treated participants and 30% of the placebo group; mild infections occurred in 7% of both groups, with no serious infections. However, a presentation filed with the SEC showed that 3 participants in the 20-milligram group and 5 in the 40-milligram group stopped treatment because of adverse events, while none in the 5-milligram or placebo groups did so. Reasons for discontinuation in the higher-dose groups included skin reactions, electrocardiogram changes, and elevated liver enzymes. The absence of serious events over the short term remains insufficient to establish safety for long-term use.

An SEC filing also recorded a median reduction of 24% in lipoprotein(a), with no increases observed in low-density lipoprotein cholesterol or triglycerides. This provides additional leads for further research, but remains a biomarker finding. The company explicitly cautioned in its presentation that these changes may not translate into clinical benefit; all currently available data also come from the company’s announcements and regulatory disclosures.

Next, Monte Rosa plans to initiate the Phase 2b GFORCE-2 trial in the first half of 2027, treating patients with stable coronary artery disease and persistent inflammation for six months, with assessments combining cardiovascular imaging and biomarkers. The study design remains subject to regulatory feedback, and preclinical toxicology studies supporting a longer treatment course still need to be completed. The company also plans Phase 2 trials in gout and hidradenitis suppurativa. The gout study will test whether the drug can prevent recurrent flares, with preliminary data expected in the second half of 2027. These studies will progressively address whether lowering inflammatory signals can deliver improvements that patients can actually experience.